Form 4: United Therapeutics CEO Executes Stock Options

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed and sold common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in a series of stock option exercises and subsequent sales of common stock.
• On October 3, 2025, 4,000 stock options were exercised at a price of $120.26 per share.
• Following the exercise on October 3, 2025, shares were sold in multiple transactions: 1,000 shares at $443.63, 1,629 shares at a weighted average price of $445.6121, and 1,371 shares at a weighted average price of $448.8074.
• On October 6, 2025, an additional 4,000 stock options were exercised at a price of $120.26 per share.
• Subsequently on October 6, 2025, shares were sold: 1,000 shares at $445.24 and 3,000 shares at a weighted average price of $451.175.
• All reported transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established by the reporting person on May 2, 2025.
• The 10b5-1 plan is designed to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, direct beneficial ownership of common stock is 130 shares, with indirect ownership totaling 644,393 shares held by spouse and various family trusts.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercises and sales) conducted under a pre-arranged 10b5-1 trading plan. Such planned transactions are generally considered neutral as they reflect personal financial management rather than a change in the company's fundamental outlook or management's confidence.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a systematic approach to managing equity compensation rather than reactive selling based on new, non-public information.
• The significant difference between the exercise price ($120.26) and the sale prices (ranging from $443.63 to $451.175) indicates substantial profitability for the insider on these option exercises.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially signaling a lack of further upside, although this is mitigated by the pre-planned nature.

Future Outlook

The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The exercise and sale of stock options were pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine aspect of executive compensation management in publicly traded companies across all industries. These filings provide transparency into how executives manage their equity holdings, often for diversification or liquidity purposes, and are generally not indicative of specific company or industry-wide performance trends unless they deviate significantly from established patterns or are unscheduled.

Related Party Transactions

• Indirect beneficial ownership includes shares held by spouse and various family trusts (324,518 shares by Trust (5), 258,117 shares by Trust (6), 45,596 shares by Trust (7), 15,962 shares by Trust (8)).

Stakeholder Impact

• Shareholders gain transparency into executive equity management, noting the profitability of the option exercises.
• The pre-arranged nature of the sales under a 10b5-1 plan minimizes potential negative market sentiment often associated with insider selling.

Next Steps

• Continuation of the 10b5-1 trading plan for the remaining tranche of 294,000 stock options until exhaustion or December 31, 2025.

Key Dates

Recommendation

The filing details routine insider stock option exercises and sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are common for executives managing their equity compensation and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

UTHR, United Therapeutics, Form 4, insider trading, stock options, 10b5-1 plan, Martine Rothblatt, CEO, Director, equity compensation